Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)

NCT03371719 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT03371719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03371719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Lead sponsor
NRG Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 20, 2018
Completion date
March 10, 2030
Enrollment
298 (actual)
Sites
360

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent prostate carcinoma, stage iii prostate adenocarcinoma ajcc v7, stage iv prostate adenocarcinoma ajcc v7